Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26/MVA Mosaic Therapeutic Vaccine in HIV-1
NCT02919306Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2016
- Primary completion
- Sep 2018
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Ad26.Mos4.HIV, MVA-Mosaic in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Started Sep 2016; status: completed.
02
Drugs
Ad26.Mos4.HIVMVA-Mosaic
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02919306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919306.